Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease

A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company’s following moved the wrong way. Tilray Brands shares are at $3.56, down 4% this morning, as the company’s cannabis sales contracted while its beer and distribution units carried the top line.

Meanwhile, Canopy Growth (NASDAQ:CGC) stock trades at $0.87, down 1%, a far softer slide than the drop hitting Tilray Brands stock. At the same time, Aurora Cannabis (NASDAQ:ACB) shares are at $4.41, down 1%, another modest retreat for a pure-play cannabis producer.

As a gauge of the wider cannabis group, the Amplify Alternative Harvest ETF (NYSEARCA:MJ) is at $24.31, down 0.3%. For a broad-market read, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is at $774.83, down 0.3%. That spread marks the selloff as a reaction to Tilray’s own numbers, since the cannabis fund and the S&P 500 fund are each slipping far less.

Shrinking Cannabis Sales Undercut a Revenue Record

At first glance, Tilray delivered. Its net revenue for Q1 FY2027 rose 23% year over year to a first-quarter record, while its gross margin expanded and its gross profit hit a new high for the period. Tilray’s cannabis net revenue fell to $56.1 million from the prior-year period, making that business the one major segment to shrink. Beer led the gains, as the company’s beverage revenue grew sharply following the BrewDog acquisition and its distribution sales rose too.

Its profitability slipped anyway, as Tilray’s adjusted earnings before interest, taxes, depreciation and amortization declined year over year despite the higher revenue and gross profit, and the company pointed to global fuel surcharges as one burden on the quarter and reaffirmed its full-year adjusted earnings guidance. On the balance sheet, Tilray Brands said it ended the quarter in a net cash position and has reduced outstanding debt during the fiscal year to date.

Beer and Distribution Prop Up the Top Line

Tilray Brands now spans cannabis, beverage, distribution and wellness, so beer and pharmaceutical wholesaling can carry group revenue to a record while the cannabis business contracts underneath. Chief Executive Irwin D. Simon leaned into that mix when presenting Tilray’s results, stating, “We are no longer dependent on a single market or regulatory catalyst.”

Canopy Growth and Aurora Cannabis remain far more concentrated in cannabis itself. That’s why a Tilray quarter built on beer and pharmaceutical distribution doesn’t read across directly to either company.

What to Watch Next

The focus turns to whether Tilray Brands’ cannabis segment stabilizes over the coming quarters, since the revenue record now leans heavily on beer and distribution. The company’s reaffirmed full-year guidance sets a clear bar for the remainder of the fiscal year. A return to growth in Tilray’s cannabis business could cast this quarter as a temporary dip.

Traders may want to keep an eye on whether fuel-surcharge pressure on Tilray’s adjusted earnings eases, since that burden helped push profitability lower despite record sales. Canopy Growth and Aurora Cannabis offer a cleaner read on cannabis demand, so further weakness in Canopy Growth stock or Aurora Cannabis stock could point to a problem extending beyond Tilray.

Contact [email protected] for any questions or corrections.